Bladder CancerFDA Approvals, News & Updates
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
By Laura Morgan
Take a look at the 5 new promising immunotherapies approved by the FDA for bladder cancer after decades of no new treatment options for this type of cancer.
Results 1 - 5 of 5